CN102439175A - 免疫调节治疗剂 - Google Patents

免疫调节治疗剂 Download PDF

Info

Publication number
CN102439175A
CN102439175A CN2010800203608A CN201080020360A CN102439175A CN 102439175 A CN102439175 A CN 102439175A CN 2010800203608 A CN2010800203608 A CN 2010800203608A CN 201080020360 A CN201080020360 A CN 201080020360A CN 102439175 A CN102439175 A CN 102439175A
Authority
CN
China
Prior art keywords
fibrinopeptide
disease
peptides
patient
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800203608A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·J·梅林
威德·M·梅林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102439175A publication Critical patent/CN102439175A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
CN2010800203608A 2009-03-09 2010-03-09 免疫调节治疗剂 Pending CN102439175A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15852609P 2009-03-09 2009-03-09
US61/158,526 2009-03-09
PCT/US2010/026665 WO2010104854A2 (en) 2009-03-09 2010-03-09 Immunomodulatory therapeutic agents

Publications (1)

Publication Number Publication Date
CN102439175A true CN102439175A (zh) 2012-05-02

Family

ID=42729052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800203608A Pending CN102439175A (zh) 2009-03-09 2010-03-09 免疫调节治疗剂

Country Status (13)

Country Link
US (1) US20110318375A1 (https=)
EP (1) EP2405935A2 (https=)
JP (1) JP2012520306A (https=)
KR (1) KR20120008029A (https=)
CN (1) CN102439175A (https=)
AU (1) AU2010222851A1 (https=)
BR (1) BRPI1009569A2 (https=)
CA (1) CA2753871A1 (https=)
EC (1) ECSP11011373A (https=)
MX (1) MX2011009475A (https=)
RU (1) RU2011137856A (https=)
SG (1) SG174290A1 (https=)
WO (1) WO2010104854A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110045130A (zh) * 2019-04-17 2019-07-23 中山大学附属第一医院 一种与IgA肾病相关的多肽的免疫分析检测试剂盒

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837358B (zh) 2012-12-14 2019-03-29 希尔氏宠物营养品公司 用于陪伴动物的抗衰老食物
EP3439683A4 (en) * 2016-04-04 2020-07-29 Marpe Holdings, LLC MODULATION OF THE IMMUNE SYSTEM FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS
JP2018163071A (ja) * 2017-03-27 2018-10-18 京都府公立大学法人 関節リウマチに関するペプチドマーカー
WO2025017038A2 (en) * 2023-07-17 2025-01-23 Angus Dalgleish Serum-derived peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086947A1 (en) * 1999-06-30 2004-05-06 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
CN1856504A (zh) * 2002-02-06 2006-11-01 维克技术有限公司 抗梗塞分子
US20080294261A1 (en) * 2007-05-24 2008-11-27 Kevin Pauza Method for treating herniated discs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086947A1 (en) * 1999-06-30 2004-05-06 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
CN1856504A (zh) * 2002-02-06 2006-11-01 维克技术有限公司 抗梗塞分子
US20080294261A1 (en) * 2007-05-24 2008-11-27 Kevin Pauza Method for treating herniated discs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110045130A (zh) * 2019-04-17 2019-07-23 中山大学附属第一医院 一种与IgA肾病相关的多肽的免疫分析检测试剂盒
CN110045130B (zh) * 2019-04-17 2022-03-29 中山大学附属第一医院 一种与IgA肾病相关的多肽的免疫分析检测试剂盒

Also Published As

Publication number Publication date
RU2011137856A (ru) 2013-04-20
CA2753871A1 (en) 2010-09-16
KR20120008029A (ko) 2012-01-25
ECSP11011373A (es) 2011-11-30
SG174290A1 (en) 2011-10-28
WO2010104854A3 (en) 2010-11-04
BRPI1009569A2 (https=) 2016-03-22
AU2010222851A1 (en) 2011-09-15
US20110318375A1 (en) 2011-12-29
EP2405935A2 (en) 2012-01-18
JP2012520306A (ja) 2012-09-06
MX2011009475A (es) 2011-12-08
WO2010104854A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
IL129211A (en) Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders
CN102439175A (zh) 免疫调节治疗剂
CN102458478A (zh) 白蛋白-淀粉样肽缀合物及其用途
EP3522921B1 (en) Prevention of allergy
CN103435692A (zh) 人参糖蛋白在治疗老年痴呆的药物和保健食品中的应用
Czajka et al. Mechanism of Vipera berus venom activity and the principles of antivenom administration in treatment
JP7163547B2 (ja) 新規ペプチドおよびその用途
WO2011091344A1 (en) Pan-antiviral peptides for protein kinase inhibition
JP3054194B2 (ja) 免疫抑制生産物
Ichiki et al. Cleavage of bacterial flagellin with proteolytic enzymes: II. Induction of enhanced delayed-type hypersensitivity to flagellin by peptic fragments of the protein
AU2012285710B2 (en) Dosage of DnaK
RU2405560C1 (ru) Средство для защиты клеток мозга
WO2010142997A1 (en) Use of a serum composition to reduce the levels of tnf and/or vegf in mammals
KR102946895B1 (ko) SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도
JPH029600B2 (https=)
US20180264091A1 (en) Enzymatic fractions with anti-inflammatory activity
CN1128810C (zh) 防治肝病的鲨鱼肝多肽结构及纯化
Mori et al. Venom and antivenom of the redback spider (Latrodectus hasseltii) in Japan. Part II. Experimental production of equine antivenom against the redback spider
CN108484760A (zh) 一种抗蓖麻毒素免疫球蛋白F（ab’）2及其制备方法
KR100538642B1 (ko) 목질진흙버섯으로부터 분리한 산성 프로테오-헤테로글리칸추출물을 함유하는 관절염 치료용 또는 예방용 조성물
US20220079999A1 (en) Antivenom compositions and uses thereof
CN1169834C (zh) 从人血浆中分离纯化巨核细胞刺激因子的方法及应用
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
CN117903237A (zh) 一种制备胎盘抗原肽复合物的工艺及其应用
CN120966834A (zh) 一种靶向FcRn和FcγRs的双特异性纳米抗体及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120502